Population-based study of screening test performance indices of three human papillomavirus DNA tests
(2007) In Journal of Medical Virology 79(8). p.1169-1175- Abstract
- In order to evaluate three common human papillomavirus (HPV) DNA tests for key performance indices in population-based cervical screening, we sampled 12,527 women aged 3238 years who attended invitational, population-based screening and followed them for 4 years with comprehensive registry linkages. Three different HPV DNA tests (GP5+/6+general primer PCR (using either AmpliTaq or AmpliTaq Gold DNA polymerase), Amplicor (TM) PCR and Hybrid Capture II (TM) were evaluated using baseline samples from women who on follow-up developed cervical intraepithelial neoplasia grade 2 or worse (CINII+) (n =197) as well as a representative subsample of the women in the cohort (n =794). The population-based HPV prevalence, sensitivity for future cervical... (More)
- In order to evaluate three common human papillomavirus (HPV) DNA tests for key performance indices in population-based cervical screening, we sampled 12,527 women aged 3238 years who attended invitational, population-based screening and followed them for 4 years with comprehensive registry linkages. Three different HPV DNA tests (GP5+/6+general primer PCR (using either AmpliTaq or AmpliTaq Gold DNA polymerase), Amplicor (TM) PCR and Hybrid Capture II (TM) were evaluated using baseline samples from women who on follow-up developed cervical intraepithelial neoplasia grade 2 or worse (CINII+) (n =197) as well as a representative subsample of the women in the cohort (n =794). The population-based HPV prevalence, sensitivity for future cervical intraepithelial neoplasia grade 2 or worse (CINII+), and absolute risk of CINII+ was 7.1%, 87.1%, and 23.2% for AmpliTaq GP5+/6+ PCR, 11.9%, 88.9%, and 11.0% for AmpliTaq Gold GP5+/6+ PCR, 15.7%, 93.4%, and 9.8% for Amplicor, 10.0%, 92.9%, and 15.3% for Amplicor with raised cut-off, and 7.8%, 79.7%, and 16.9% for Hybrid Capture II. In conclusion, AmpliTaq GP5+/6+ PCR and Amplicor with raised cut-off value have adequate performance indices for primary screening. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/646388
- author
- Wahlström, Cecilia LU ; Iftner, Thomas ; Dillner, Joakim LU and Dillner, Lena LU
- organization
- publishing date
- 2007
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- longitudinal cohort study, cervical cancer, PCR
- in
- Journal of Medical Virology
- volume
- 79
- issue
- 8
- pages
- 1169 - 1175
- publisher
- John Wiley & Sons Inc.
- external identifiers
-
- wos:000247642200018
- scopus:34347334426
- pmid:17596834
- ISSN
- 1096-9071
- DOI
- 10.1002/jmv.20898
- language
- English
- LU publication?
- yes
- id
- cc555a40-3beb-4cdc-bb91-77479738d504 (old id 646388)
- date added to LUP
- 2016-04-01 12:15:13
- date last changed
- 2022-01-27 01:06:22
@article{cc555a40-3beb-4cdc-bb91-77479738d504, abstract = {{In order to evaluate three common human papillomavirus (HPV) DNA tests for key performance indices in population-based cervical screening, we sampled 12,527 women aged 3238 years who attended invitational, population-based screening and followed them for 4 years with comprehensive registry linkages. Three different HPV DNA tests (GP5+/6+general primer PCR (using either AmpliTaq or AmpliTaq Gold DNA polymerase), Amplicor (TM) PCR and Hybrid Capture II (TM) were evaluated using baseline samples from women who on follow-up developed cervical intraepithelial neoplasia grade 2 or worse (CINII+) (n =197) as well as a representative subsample of the women in the cohort (n =794). The population-based HPV prevalence, sensitivity for future cervical intraepithelial neoplasia grade 2 or worse (CINII+), and absolute risk of CINII+ was 7.1%, 87.1%, and 23.2% for AmpliTaq GP5+/6+ PCR, 11.9%, 88.9%, and 11.0% for AmpliTaq Gold GP5+/6+ PCR, 15.7%, 93.4%, and 9.8% for Amplicor, 10.0%, 92.9%, and 15.3% for Amplicor with raised cut-off, and 7.8%, 79.7%, and 16.9% for Hybrid Capture II. In conclusion, AmpliTaq GP5+/6+ PCR and Amplicor with raised cut-off value have adequate performance indices for primary screening.}}, author = {{Wahlström, Cecilia and Iftner, Thomas and Dillner, Joakim and Dillner, Lena}}, issn = {{1096-9071}}, keywords = {{longitudinal cohort study; cervical cancer; PCR}}, language = {{eng}}, number = {{8}}, pages = {{1169--1175}}, publisher = {{John Wiley & Sons Inc.}}, series = {{Journal of Medical Virology}}, title = {{Population-based study of screening test performance indices of three human papillomavirus DNA tests}}, url = {{http://dx.doi.org/10.1002/jmv.20898}}, doi = {{10.1002/jmv.20898}}, volume = {{79}}, year = {{2007}}, }